ABSTRACT: Tumors create and maintain an immunosuppressive microenvironment that promotes cancer cell escape from immune surveillance. The immune checkpoint protein programmed deathligand 1 (PD-L1) is expressed in many cancers and is an important contributor to the maintenance of the immunosuppressive tumor microenvironment. PD-L1 is a prominent target for cancer immunotherapy. Guidance of anti-PD-L1 therapy is currently effected through measurement of PD-L1 through biopsy and immunohistochemistry. Here, we report a peptide-based imaging agent, [
■ INTRODUCTION
Immuno-oncology is revolutionizing cancer therapy by producing durable responses that lead to improved survival of patients with a variety of malignancies. The immune checkpoint protein programmed death ligand 1 (PD-L1) is one important target of those therapeutic efforts. PD-L1 is expressed in many tumors as an immune evasion mechanism. 1 Measurement of PD-L1 through biopsy and immunohistochemistry (IHC) is used to select patients for therapy and for therapeutic monitoring in those undergoing anti-PD-L1 axis treatment. 2, 3 However, PD-L1 IHC has significant limitations, including conflicting results between different detection antibodies, insufficient interassay agreement, and heterogeneity in PD-L1 expression within and across tumor sites. 4 Also, PD-L1 expression in the tumors is temporally dynamic, and these changes are difficult to capture during therapy as repeat biopsy is often impractical. 5 Those issues are compounded in patients with advanced stage disease, a population in which immune checkpoint inhibitors are currently investigated. Noninvasive quantification of total PD-L1 expression in all lesions concurrently could address some of those limitations and assist in therapeutic decision-making.
Noninvasive imaging technologies such as positron emission tomography (PET) can provide quantitative, real-time assessment of target expression and dynamics that enable therapeutic monitoring. 6, 7 We and others have demonstrated the potential of radiolabeled anti-PD-L1 antibodies, nanobodies, and small proteins to image PD-L1 expression in different tumor models. 8−14 In spite of those promising developments, the relatively longer biological half-lives of radiolabeled antibodies in clinical trials necessitate a wait period of 4 to 7 days to get high tissue contrast. 15 This could potentially delay a switch to alternative treatment. Thus, for rapid and accurate imaging of PD-L1 dynamic changes during treatment, novel probes with shorter biological half-lives are needed. Such probes provide opportunities to better select patients in relatively shorter periods of time early during treatment. Specially, small peptide and low-molecular-weight imaging agents often exhibit faster pharmacokinetics (minutes to hours) than small proteins and antibodies (hours to days), and produce high-contrast images within a clinically useful time frame. Not surprisingly, most routinely used clinical radiopharmaceuticals, particularly for PET, are either peptides or low-molecular-weight agents. 16 High-affinity peptide-based PD-L1 inhibitors have recently been reported. 17 The pharmacokinetics of those peptides, however, have not been matched with routinely used PET radionuclides such as 68 Ga or 18 F. Our recently reported cyclic 14-amino-acid peptide, its 1,4,7,10-tetraazacyclododececane,1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA) conjugate (WL12), and copper-chelated analogs ([ 64 Cu]WL12) demonstrated high in vitro PD-L1 binding affinity (IC50= 2.9 nM for the metalated version) and in vivo specific tumor targeting ability. 18 With the promising results observed using [ 64 Cu]-WL12, our attention has turned to generating a similar compound radiolabeled with 68 Ga. Interest for 68 Ga for imaging applications comes from its ready availability from a generator, its routine use in many clinical centers, and the 67.6 min half-life of 68 Ga, which results in low radiation exposure. Also, 68 Ga half-life matches well with the pharmacokinetic properties of peptides. Additionally, kit type preparation similar to that of 99m Tc is feasible. Recently clinical applications of 68 Ga-based radiotracers have been increasing, 19 A PD-L1-targeted imaging agent that leverages the benefits of 68 Ga for PET has not been reported. The rapid normal tissue clearance observed with WL12 is optimal for the short physical half-life of 68 Ga. ■ EXPERIMENTAL SECTION Materials. WL12 was custom synthesized by CPC Scientific (Sunnyvale, CA) with >95% purity and 2,2′,2″-(10-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid (DOTAGA anhydride) was purchased from CheMatech Macrocycle Design Technologies (catalog #C109; Dijon, France). All other chemicals were purchased from Sigma-Aldrich or Fisher Scientific unless otherwise specified. Eckert and Ziegler 68 Ge/ 68 Ga-generator was used as a 68 Ga source, and 68 Ga was eluted using 0.5 N HCl solution. TraceSELECT grade water and sodium acetate were used for 68 Ga labeling. All cell culture related reagents were purchased from Invitrogen.
Synthesis of DOTAGA Conjugated PD-L1 Binding Peptide (WL12). DOTAGA conjugated WL12 was synthesized and characterized according to our previously published procedure. 18 Briefly, to a solution of WL12 (3 mg, 1.5 μmol) and diisopropylethylamine (20.0 μL, 0.2 μmol) in 1.0 mL of dimethylformamide (DMF) was added DOTAGA anhydride (3.7 mg, 7.51 μmol), and the reaction mixture was stirred for 2 h at room temperature. The reaction mixture was purified on a reversed phase high performance liquid chromatography (RP-HPLC) system using a semipreparative C-18 Luna column (5 μm, 10 × 250 mm, Phenomenex, Torrance, CA). The HPLC column was eluted with (A) methanol (0.1% TFA) and (B) water (0.1% TFA) using a linear gradient from 2/98 (A/B) to 100/0 (A/B) over 60 min at a flow rate of 4 mL/min. The desired DOTAGA conjugated WL12 was collected at 44.5 min, solvent evaporated, residue dissolved in deionized water, and lyophilized to form a solid product. The purified WL12-DOTAGA was characterized by electrospray ionization mass spectroscopy.
Radiolabeling and Purification of [ 68 Ga]WL12. A fractionation method was used for 68 Ga elution. The generator was eluted with 0.5 N HCl solution, 30 the first fraction (1.0 mL) was discarded, and the next fraction (2.0 mL) containing >85% of radioactivity was transferred into a reaction vial containing WL12 peptide (30 μg) and 0.5 N sodium acetate buffer (600 μL, pH 4.5). The pH of the final reaction was 3.5− 4.0. 68 Ga radiolabeling was performed without stirring at 100°C for 10 min. After completion, a sample (∼20 μL) was analyzed for radiochemical purity by RP-HPLC. The cooled crude reaction mixture was passed through a preconditioned C-18 Sep-Pak cartridge, rinsed with 10 mL of ultrapure water, and eluted with 1.0 mL of ethanol. Preconditioning of the cartridge was performed with 5 mL of methanol followed by 10 mL of water. The radiochemical purity of Sep-Pak purified [ 68 Cell Lines. Chinese hamster ovary cell line CHO-K1 (CHO) and triple negative breast cancer (TNBC) cell line MDAMB231 were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and passaged for fewer than 3 months after which new cultures were initiated from vials of frozen cells. All other cell lines were cultured in ATCC recommended media in an incubator at 37°C in an atmosphere containing 5% CO 2 . CHO cell line stably expressing human PD-L1 (hPD-L1) was generated in our laboratory 10 and maintained in F-12K medium with 10% FBS, 1% P/S, and 2 mg/mL G418. The SUM149 cell line was kindly provided by Dr. Stephen P. Ethier, Medical University of South Carolina, and authenticated by STR profiling at JHU. SUM149 cells were maintained in Ham's F-12 medium with 5% FBS, 1% P/S, 5 mg/mL insulin, and 0.5 mg/mL hydrocortisone.
Flow Cytometry Analysis for PD-L1 Expression in Cell Lines. Surface PD-L1 expression levels were analyzed using an anti-human PD-L1 antibody conjugated with phycoerythrin (BD-MIH1-PE, clone # MIH1, catalog #557924) according to procedures described previously. 18 Immunohistochemistry. Tumor sections were evaluated for PD-L1expression by immunohistochemistry (IHC). Harvested tumors were fixed in 10% neutral buffered formalin and embedded in paraffin, and 4 μm thick sections were obtained on slides. After deparaffinizing with xylene and alcohol gradients, antigen retrieval was done using 10 mM citrate buffer, pH 6.0 (#S1699, Dako target retrieval solution). Tumor sections were then treated with 3% H 2 O 2 for 10 min, blocked with 5% goat serum for 1 h, and then incubated with a primary antihuman PD-L1 antibody (#13684, Cell Signaling) at 1:500 dilution at 4°C overnight. Subsequently, using Dako CSAII Biotinfree Tyramide Signal Amplification System kit, slides were incubated with secondary antibody, amplification reagent and with antifluorecein-HRP. Finally, staining was carried out by adding DAB chromogen. Sections were counterstained with hematoxylin, followed by dehydration with alcohol gradients, xylene washes, and mounted with a coverslip.
Animal Models. Animal studies were performed according to the protocols approved by the JHU Animal Care and Use Committee using six-to-eight-week-old, female, nonobese Ga]WL12 intravenously, anesthetized under 3% isofluorane prior to being placed on the scanner. PET images were acquired in two bed positions at 10 min/bed in an ARGUS small-animal PET-CT scanner (Sedecal, Madrid, Spain) as described previously.
14 For hPD-L1 and CHO tumor bearing mice (n = 3), the whole-body PET images were acquired at 15, 60, and 120 min after injection of radiotracer. For MDAMB231 and SUM149 tumor models (n = 3), mice were imaged at 60 min after [ Ga ] standards, which were measured in triplicate. Biodistribution data shown is mean ± standard error of the mean (SEM).
Data Analysis. Statistical analysis was performed using the Prism 6 Software (GraphPad Software, La Jolla, CA). P-values < 0.05 were considered to be significant using an unpaired two tailed t test, and the comparative reference was cell line or tumor with low PD-L1 expression. Figure 1A ). Our 68 Ga generator was one year old and yielded approximately 3.7 × 10 7 Bq (1 mCi) activity to start with; however, the synthesis procedures used consistently yielded >80 ± 5% (decay corrected) radiochemically pure [ 68 Ga]WL12 and with a low specific activity of 128 GBq/μmol. The labeling and purification methods we have tested here can be easily modified to develop a kit-based preparation of [ 68 Ga ]WL12 uptake in the tumor is PD-L1 specific. In addition to tumors, high uptake was observed in kidneys that are involved in excretion of the tracer. High uptake was also observed in the liver ( Figure 2B ). To validate our PET imaging observations, biodistribution studies were performed at 15, 60, and 120 min time points (Figure 3) . Biodistribution studies showed greater than 9-fold increase of [ 68 Ga]WL12 accumulation in hPD-L1 tumors at all the time points tested, compared to control CHO tumors ( Figure 3A) . The percentage of injected dose per gram of tissue (%ID/g) for hPD-L1 tumors was 19.4 ± 3.3, 11.56 ± 3.18, and 9.89 ± 1.72 at 15, 60, and 120 min after injection, respectively. In contrast, control CHO control tumors showed <1.33 ± 0.21 uptake of [ 68 Ga]WL12 at the same time points. The PD-L1-mediated uptake of [ 68 Ga]WL12 in hPDL-1 tumors was further confirmed by reduced uptake of radioactivity observed in the blocking experiment. In blocking dose mice, approximately 75% decrease in the uptake of radioactivity in hPD-L1 tumors (5.1 ± 0.2) was observed at 60 min compared to mice that did not receive the blocking dose.
The high PD-L1 specific accumulation of [ 68 Ga]WL12 in PD-L1 positive tumors resulted in tumor-to-muscle ratios of 59.79 ± 16.47 and 100.47 ± 61.23 at 60 and 120 min, respectively. The tumor-to-blood ratios of 7.56 ± 16.47 and 16.02 ± 3.40 at 60 and 120 min, respectively, showed fast clearance of the tracer from circulation. The imaging and biodistribution results were consistent with IHC data that showed intense PD-L1 immunoreactivity in hPD-L1 tumors and not in control CHO tumors ( Figure 2C ).
[ 68 Ga]WL12 showed better image contrast at 60 and 120 min after administration compared to [
64 Cu]WL12. 18 The blood %ID/g values at 60 and 120 min were 3.3 ± 0.4 and 0.6 ± 0.01 for [ 68 Cu]WL12, it was 34.3 ± 3.1 and 24.2 ± 2.5%, respectively, at the same time points. Differences were also observed in kidney uptake. The kidney uptake (%ID/g) for [ 68 Ga]WL12 at 60 min was 64.7 ± 12.1 and rapidly reduced to 27.67 ± 4.09 at 120 min, whereas kidney uptake of [ 64 Cu]WL12 was 34.3 ± 3.1 and 27.7 ± 2.7% ID/g at 60 and 120 min, respectively. Taken together, these data indicate faster clearance of [ 68 Ga]WL12 that results in high contrast images. Supporting those observations, the hPD-L1 tumor-to-muscle and hPD-L1 tumor-to-blood ratios at 120 min were 100.47 ± 61. 23 Ga ]WL12 image contrast could be further improved with the coadministration of lysine, or a mixture of similar positively charged amino acids, to reduce kidney accumulation of radioactivity. 34 Those strategies were also shown to be effective in reducing radiotoxicity associated with renal clearance. 34 Taken together, these results demonstrate that [ 68 Ga]WL12 provides suitable contrast for rapid imaging of PD-L1 expression and dynamics in tumors.
Radiolabeled antibodies, PD-1 derived fragments and adnectin derived small proteins (∼10 kDa), have been reported for PD-L1 detection in contrast to our small peptides (2 kDa). [8] [9] [10] 12, 13, 35 All those agents provide PD-L1 specific images albeit requiring longer clearance times that span days to hours in contrast to our small peptides that require <60 min. Additionally, the advantage of small peptides and the potential to modify their biodistribution was evident in the different pharmacokinetics and image contrast shown by [ 68 Ga-labled peptide, due to increased hydrophilicity, shows improved image contrast. It would be difficult to manipulate the pharmacokinetics of small proteins in a similar fashion. Also, manufacturing of biologicals is more complex, costly, time-consuming and challenging than chemically based peptides. Advancement of a radiolabeled biopharmaceutical adds an extra layer of complexity and logistical challenges compared to small molecules and peptides.
Validation of PD-L1 Specificity of [ 68 Ga ]WL12 uptake in MDAMB231 and SUM149 tumors was 4.97 ± 0.8 and 1.9 ± 0.1%ID/g (P < 0.01) at 60 min, respectively ( Figure 4C) . [ 68 Ga]WL12 uptake in MDAMB231 tumors is significantly higher than both control tumors (SUM149 and CHO) and lower than the hPD-L1 tumors that have nearly 7-fold high PD-L1 expression. These results validate that [ 68 Ga]WL12 has the potential to detect variable PD-L1 expression levels in the tumors. Blocking dose of WL12 resulted in >50% reduction in [ 68 Ga]WL12 uptake in MDAMB231 tumors. Because in vivo studies were performed sequentially in these tumor models, we speculate that low specific activity and nonspecific uptake associated with the agent may have contributed to the differences in normal tissue uptake. No significant difference in uptake was observed in SUM149 tumors or any other tissues in blocking dose mice, underlining the specificity of [ 68 Ga]-WL12 for human PD-L1. IHC analysis of the collected tumors for PD-L1 expression showed intense immunoreactivity in MDAMB231 tumors ( Figure 4D ) but not in SUM149 xenografts, further validating flow cytometry, imaging, and biodistribution results. Normal tissue distribution observed in breast tumor model was similar to that observed in hPD-L1/ CHO tumor model, with kidney (65.6 ± 3.6% ID/g) and liver (11.4 ± 0.7% ID/g) showing high radioactivity accumulation. Taken together, our results establish that [ 68 Ga]WL12 is capable of detecting variable PD-L1 expression levels in the tumors with high specificity.
The ultimate proof of an imaging agent specificity to its target is characterized by in vivo experiments such as PET imaging and biodistribution studies. Our in vivo PET imaging and biodistribution studies in four different tumor models clearly demonstrate the high PD-L1 binding specificity of [ 68 
■ CONCLUSION
We demonstrated the specificity of [ 68 Ga]WL12 to detect PD-L1 expression in multiple xenograft models with variable PD-L1 expression and described its biodistribution and pharmacokinetics. In addition, the radiolabeling and purification conditions tested for preparation of [ 68 Ga]WL12 can be easily modified to facilitate a kit preparation of the radiotracer for PD-L1 imaging. Such 68 Ga labeled PD-L1 imaging agents with short biological half-life and fit within the routine clinical work flow can enable therapy monitoring and stratification of patients in the field of immuno-oncology and globally without the necessity for accelerators.
